BR0313655A - Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável - Google Patents

Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável

Info

Publication number
BR0313655A
BR0313655A BR0313655-8A BR0313655A BR0313655A BR 0313655 A BR0313655 A BR 0313655A BR 0313655 A BR0313655 A BR 0313655A BR 0313655 A BR0313655 A BR 0313655A
Authority
BR
Brazil
Prior art keywords
sulfonamide
pyridine
methoxy
phenyl
methylpyrazin
Prior art date
Application number
BR0313655-8A
Other languages
English (en)
Inventor
David William Tonge
Sian Tomiko Taylor
Francis Thomas Boyle
Andrew Mark Hughes
Donna Johnstone
Marianne Bernice Ashford
Nigel Charles Barrass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0313655(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0313655A publication Critical patent/BR0313655A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE N-(3-METóXI-5-METIILPIRAZIN-2-IL)-2-(4-[1,3,4-OXADIAZOL-2-IL] FENIL)PIRIDINA-3-SULFONAMIDA, OU UM SAL DO MESMO FARMACEUTICAMENTE ACEITáVEL". O uso de N-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridina-3 -sulfonamida, ou um sal do mesmo farmaceuticamente aceitável, no tratamento de câncer e/ou dor em Um animal de sangue quente tal como o homem é descrito.
BR0313655-8A 2002-08-23 2003-08-20 Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável BR0313655A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use
PCT/GB2003/003653 WO2004018044A2 (en) 2002-08-23 2003-08-20 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent

Publications (1)

Publication Number Publication Date
BR0313655A true BR0313655A (pt) 2005-06-21

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313655-8A BR0313655A (pt) 2002-08-23 2003-08-20 Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável

Country Status (32)

Country Link
US (2) US7820679B2 (pt)
EP (2) EP1545710B1 (pt)
JP (2) JP3663202B2 (pt)
KR (1) KR20050035280A (pt)
CN (1) CN100467023C (pt)
AR (1) AR041037A1 (pt)
AT (1) ATE427773T1 (pt)
AU (1) AU2003255835B8 (pt)
BR (1) BR0313655A (pt)
CA (1) CA2496476C (pt)
CL (1) CL2003001692A1 (pt)
CY (1) CY1110712T1 (pt)
DE (1) DE60327084D1 (pt)
DK (1) DK1545710T3 (pt)
ES (1) ES2323309T3 (pt)
GB (1) GB0219660D0 (pt)
HK (1) HK1077534A1 (pt)
IL (1) IL166730A0 (pt)
IS (1) IS2704B (pt)
MX (1) MXPA05001862A (pt)
MY (2) MY136449A (pt)
NO (1) NO330756B1 (pt)
NZ (1) NZ538114A (pt)
PL (1) PL375561A1 (pt)
PT (1) PT1545710E (pt)
RU (1) RU2340343C2 (pt)
SA (1) SA03240363B1 (pt)
SI (1) SI1545710T1 (pt)
TW (1) TWI302912B (pt)
UA (1) UA82071C2 (pt)
WO (1) WO2004018044A2 (pt)
ZA (1) ZA200501267B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (ja) * 2006-03-28 2007-10-04 Osaka Bioscience Institute 血管新生ならびに癌細胞のmesenchymal型およびamoeboid型浸潤を阻害するための薬剤
WO2009024820A2 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Therapeutic treatment 014
ATE536893T1 (de) * 2007-10-12 2011-12-15 Astrazeneca Ab Zibotentan zusammensetzung mit mannitol und mikrokristalliner zellulose
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2010004337A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
KR20140032430A (ko) * 2011-05-17 2014-03-14 플렉시콘, 인코퍼레이티드 키나제 조절 및 그에 대한 적응증
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
KR101855382B1 (ko) * 2015-12-31 2018-05-04 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (pt) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (pt) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1999048530A1 (en) 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
CA2395088A1 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AR031679A1 (es) 2000-02-16 2003-10-01 Astellas Pharma Inc Una composicion farmaceutica
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
AU2002241736A1 (en) * 2000-12-21 2002-07-01 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US6987129B2 (en) 2001-03-06 2006-01-17 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
MXPA03009277A (es) 2001-04-11 2004-03-10 Abbott Lab Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2003015820A1 (fr) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
ES2315727T3 (es) 2003-12-20 2009-04-01 Merck Patent Gmbh Derivados de tetrahidroquinolina 2-(hetero-)aril-substituidos.
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
TWI302912B (en) 2008-11-11
JP3663202B2 (ja) 2005-06-22
RU2005108349A (ru) 2005-08-27
ZA200501267B (en) 2006-10-25
MY136449A (en) 2008-10-31
EP1545710B1 (en) 2009-04-08
SI1545710T1 (sl) 2009-08-31
MY137595A (en) 2009-02-27
CN1688365A (zh) 2005-10-26
PL375561A1 (en) 2005-11-28
KR20050035280A (ko) 2005-04-15
ES2323309T3 (es) 2009-07-13
EP1545710A2 (en) 2005-06-29
CA2496476C (en) 2009-08-04
JP2004083590A (ja) 2004-03-18
US7820679B2 (en) 2010-10-26
TW200409768A (en) 2004-06-16
US20110003831A1 (en) 2011-01-06
IS2704B (is) 2010-12-15
WO2004018044A2 (en) 2004-03-04
UA82071C2 (en) 2008-03-11
PT1545710E (pt) 2009-05-26
GB0219660D0 (en) 2002-10-02
WO2004018044A3 (en) 2004-05-06
AU2003255835B2 (en) 2007-04-05
NO330756B1 (no) 2011-07-04
MXPA05001862A (es) 2005-06-03
NO20050689L (no) 2005-03-21
EP2072082A3 (en) 2009-12-23
CA2496476A1 (en) 2004-03-04
NZ538114A (en) 2008-02-29
AR041037A1 (es) 2005-04-27
AU2003255835B8 (en) 2007-05-17
RU2340343C2 (ru) 2008-12-10
ATE427773T1 (de) 2009-04-15
DE60327084D1 (de) 2009-05-20
DK1545710T3 (da) 2009-06-29
IS7766A (is) 2005-03-22
CL2003001692A1 (es) 2005-01-21
CY1110712T1 (el) 2015-06-10
SA03240363B1 (ar) 2009-04-11
US20060094729A1 (en) 2006-05-04
EP2072082A2 (en) 2009-06-24
IL166730A0 (en) 2006-01-15
HK1077534A1 (en) 2006-02-17
AU2003255835A1 (en) 2004-03-11
CN100467023C (zh) 2009-03-11
JP2005097312A (ja) 2005-04-14
WO2004018044A8 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
CY1110712T1 (el) Χρηση ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδης στη θεραπευτικη αντιμετωπιση του καρκινου
TW200509934A (en) Therapeutic treatment
GB0225474D0 (en) Therapeutic agents
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ATE457171T1 (de) Kombinationstherapie substituierter oxazolidinone
MXPA03007140A (es) Derivados de carbolina.
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
GB0223038D0 (en) Therapeutic compounds
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
SE0401342D0 (sv) Therapeutic compounds
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
SE9802208D0 (sv) Novel compounds
BRPI0408295A (pt) uso de um composto
BR0314843A (pt) Novo composto
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
MY134059A (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/497 (2006.01), A61P 35/00 (2006.01), A61P